Viral Clearance Strategies in Downstream Processing

Ensuring the viral safety of biopharmaceutical products is a paramount regulatory requirement. Biological products manufactured in mammalian cell lines, such as CHO cells, carry an inherent risk of viral contamination from endogenous retroviruses or adventitious agents introduced during upstream processing. Downstream processing must therefore incorporate robust and orthogonal viral clearance steps.

Orthogonal Viral Clearance

Orthogonal methods rely on completely different physicochemical mechanisms of action to ensure that if one step is ineffective against a specific virus, another step will provide the necessary clearance. Typically, this involves a strategic combination of viral inactivation and viral removal.

Low pH Inactivation

Low pH viral inactivation is a standard step for monoclonal antibodies, usually performed immediately after Protein A elution. Holding the elution pool at a pH of 3.6 to 3.8 for 30 to 60 minutes effectively denatures the lipid envelopes of enveloped viruses, rendering them non-infectious. However, this step provides virtually no protection against non-enveloped viruses (like parvoviruses), which are highly resistant to pH changes.

Nanofiltration and Chromatography

To address non-enveloped viruses, nanofiltration is employed. This size-exclusion method uses tightly controlled pore sizes (e.g., 20 nm) to physically retain viral particles while allowing the smaller therapeutic protein to pass through. Together with the incidental clearance provided by standard chromatography steps (like Anion Exchange), these orthogonal methods ensure a wide, robust margin of safety for patients.